StockMacro
Menu

Bio-Rad Laboratories, Inc.Class A

$358.90 +21% in 6 monthsMarket cap $9.7B

BIO on XNYS, Technology, job postings

Measures activity, not value. Not investment advice.

Shares rose 25% in six months while operating margin was negative, though 12-month net income reached $1B.

  • GoodInstitutional holders up 5.6% to 413 from 391 last quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Industry
Laboratory analytical instruments (Technology)
Employees
7,450
Website
bio-rad.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $656.4M, net income $458.6M.
Quarter to 31 Dec 2021: revenue $732.8M, net income -$1.6BQuarter to 31 Dec 2021: revenue $732.8M, net income -$1.6BQuarter to 31 Mar 2022: revenue $700.1M, net income -$3.4BQuarter to 31 Mar 2022: revenue $700.1M, net income -$3.4BQuarter to 30 Jun 2022: revenue $691.1M, net income -$927.2MQuarter to 30 Jun 2022: revenue $691.1M, net income -$927.2MQuarter to 30 Sep 2022: revenue $680.8M, net income -$164.2MQuarter to 30 Sep 2022: revenue $680.8M, net income -$164.2MQuarter to 31 Dec 2022: revenue $730.3M, net income $827.7MQuarter to 31 Dec 2022: revenue $730.3M, net income $827.7MQuarter to 31 Mar 2023: revenue $676.8M, net income $69.0MQuarter to 31 Mar 2023: revenue $676.8M, net income $69.0MQuarter to 30 Jun 2023: revenue $681.1M, net income -$1.2BQuarter to 30 Jun 2023: revenue $681.1M, net income -$1.2BQuarter to 30 Sep 2023: revenue $632.1M, net income $106.3MQuarter to 30 Sep 2023: revenue $632.1M, net income $106.3MQuarter to 31 Dec 2023: revenue $681.2M, net income $349.7MQuarter to 31 Dec 2023: revenue $681.2M, net income $349.7MQuarter to 31 Mar 2024: revenue $610.8M, net income $383.9MQuarter to 31 Mar 2024: revenue $610.8M, net income $383.9MQuarter to 30 Jun 2024: revenue $638.5M, net income -$2.2BQuarter to 30 Jun 2024: revenue $638.5M, net income -$2.2BQuarter to 30 Sep 2024: revenue $649.7M, net income $653.2MQuarter to 30 Sep 2024: revenue $649.7M, net income $653.2MQuarter to 31 Dec 2024: revenue $667.5M, net income -$715.8MQuarter to 31 Dec 2024: revenue $667.5M, net income -$715.8MQuarter to 31 Mar 2025: revenue $585.4M, net income $64.0MQuarter to 31 Mar 2025: revenue $585.4M, net income $64.0MQuarter to 30 Jun 2025: revenue $651.6M, net income $317.8MQuarter to 30 Jun 2025: revenue $651.6M, net income $317.8MQuarter to 30 Sep 2025: revenue $653.0M, net income -$341.9MQuarter to 30 Sep 2025: revenue $653.0M, net income -$341.9MQuarter to 31 Dec 2025: revenue $693.2M, net income $720.0MQuarter to 31 Dec 2025: revenue $693.2M, net income $720.0MQuarter to 31 Mar 2026: revenue $592.1M, net income -$527.1MQuarter to 31 Mar 2026: revenue $592.1M, net income -$527.1MQuarter to 30 Jun 2026: revenue $651.0M, net income $371.4MQuarter to 30 Jun 2026: revenue $651.0M, net income $371.4MQuarter to 30 Sep 2026: revenue $656.4M, net income $458.6MQuarter to 30 Sep 2026: revenue $656.4M, net income $458.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $3.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$656.4M$458.6M
30 Jun 2026$651.0M$371.4M
31 Mar 2026$592.1M-$527.1M
31 Dec 2025$693.2M$720.0M
30 Sep 2025$653.0M-$341.9M
30 Jun 2025$651.6M$317.8M
31 Mar 2025$585.4M$64.0M
31 Dec 2024$667.5M-$715.8M
30 Sep 2024$649.7M$653.2M
30 Jun 2024$638.5M-$2.2B
31 Mar 2024$610.8M$383.9M
31 Dec 2023$681.2M$349.7M
30 Sep 2023$632.1M$106.3M
30 Jun 2023$681.1M-$1.2B
31 Mar 2023$676.8M$69.0M
31 Dec 2022$730.3M$827.7M
30 Sep 2022$680.8M-$164.2M
30 Jun 2022$691.1M-$927.2M
31 Mar 2022$700.1M-$3.4B
31 Dec 2021$732.8M-$1.6B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.6B $2.6B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +1.4% +5.0%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.0B -$675.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $37.71 -$24.31
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 51.3% 52.3% 49.6%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -2.4% 8.8% -7.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 39.5% -26.4% -10.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 14.3% -17.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $329.1M $336.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.7B $1.4B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $1.2B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$215.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.45
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 9.4 33.4
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.7 4.1
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 4.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.3 2.4

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Bio-Rad Laboratories, Inc.Class ABIO (this company) $9.7B9.43.7+1.4%39.5%
AvantorAVTR $10.1B29.81.5+0.9%5.1%
BrukerBRKR $8.6Bloss2.5+2.2%-3.5%
10x GenomicsTXG $6.8Bloss11.0-3.6%-10.8%
RevvityRVTY $16.2B64.05.5+4.6%8.6%
IlluminaILMN $29.2B32.66.4+5.8%19.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.2M

bought $0, sold $1.2M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.6%

413 13F filers vs 391

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

1.2M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.1

1.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+5.4%

1.1M shares sold short in the report before, 1.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

85%

85% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 67%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-11%

34 vs 38 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+0.5%

$656.4M vs $653.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-1.6%

$31.2M vs $31.7M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$260K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.0×

8 articles in the last 7 days; its usual week has 2.

Price $358.90 on 20 Nov 2026, +18% over 12 months (12-month range $241.71 to $390.34)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.4M in the last 12 months (the 12 months before: -$955K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 34 published in the last 12 months, -11% on the 12 months before.
Revenue per quarter. Revenue $656.4M in the latest quarter, +0.5% on a year earlier.
Capital spending per quarter. Capital spending $31.2M in the latest quarter, -1.6% on a year earlier.
Institutional holders (13F filers). 413 13F filers reported holding it in the latest 13F quarter, +11% on a year earlier.
Lobbying spend. Lobbying spend: $260K published in the last 12 months, -19% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
2 Sep 2026Lobbying filinglobbying engagement terminated (FORBES-TATE)
4 Aug 20268-K and other filingsRestructuring costs announced
16 Jun 2026Sharp changeShort interest spike: short interest spike, 1.5M vs usual 949K (2026-05-29); 1.2x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 1.3M vs usual 949K (2026-05-15); 1.0x the same period a year earlier
24 Apr 20268-K and other filingsDirector or officer change
24 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MMM (2025-09-30)
28 Jul 20258-K and other filingsDirector or officer change
28 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Feb 20258-K and other filingsRestructuring costs announced
1 Oct 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 583K (2024-09-13); 3.5x the same period a year earlier
20 Aug 20248-K and other filingsDirector or officer change
20 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 546K (2024-07-31); 3.8x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 1.4M vs usual 524K (2024-07-15); 4.3x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 512K (2024-06-28); 4.5x the same period a year earlier
26 Apr 20248-K and other filingsDirector or officer change
10 Apr 20248-K and other filingsDirector or officer change
20 Mar 20248-K and other filingsDirector or officer change
14 Feb 20248-K and other filingsA major agreement ended
14 Feb 20248-K and other filingsDirector or officer change
12 Dec 2023Sharp changeShort interest spike: short interest spike, 649K vs usual 287K (2023-11-30); 3.3x the same period a year earlier
7 Dec 20238-K and other filingsDirector or officer change
28 Nov 2023Sharp changeShort interest spike: short interest spike, 572K vs usual 284K (2023-11-15); 2.0x the same period a year earlier
18 Oct 2023Sharp changeLobbying on a new issue: lobbying on a new issue: DEF (2023-09-30)
17 Oct 20238-K and other filingsDirector or officer change
25 Aug 20238-K and other filingsDirector or officer change
25 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Mar 20228-K and other filingsDirector or officer change
28 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Aug 2022: -$278K published
Month from 1 Nov 2022: -$160K published
Month from 1 Mar 2023: -$849K published
Month from 1 Jun 2023: -$263K published
Month from 1 Aug 2023: -$115K published
Month from 1 Sep 2023: -$930K published
Month from 1 Nov 2023: -$196K published
Month from 1 Dec 2023: -$359K published
Month from 1 Feb 2024: -$1.0M published
Month from 1 Mar 2024: -$826K published
Month from 1 May 2024: -$148K published
Month from 1 Jun 2024: -$104K published
Month from 1 Sep 2024: -$1.2M published
Month from 1 Mar 2025: -$741K published
Month from 1 Nov 2025: -$214K published
Month from 1 May 2026: -$136K published
Month from 1 Nov 2026: -$1.2M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 18 published
Quarter from 1 Apr 2022: 11 published
Quarter from 1 Jul 2022: 20 published
Quarter from 1 Oct 2022: 6 published
Quarter from 1 Jan 2023: 12 published
Quarter from 1 Apr 2023: 7 published
Quarter from 1 Jul 2023: 14 published
Quarter from 1 Oct 2023: 8 published
Quarter from 1 Jan 2024: 3 published
Quarter from 1 Apr 2024: 6 published
Quarter from 1 Jul 2024: 13 published
Quarter from 1 Oct 2024: 18 published
Quarter from 1 Jan 2025: 13 published
Quarter from 1 Apr 2025: 10 published
Quarter from 1 Jul 2025: 13 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 15 published
Quarter from 1 Jul 2026: 12 published
Quarter from 1 Oct 2026: 5 published
Revenue per quarter
Quarter ended 31 Dec 2021: $732.8M, -7.2% on a year earlier; public on 12 Feb 2022
Quarter ended 31 Mar 2022: $700.1M, -3.7% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $691.1M, -3.5% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $680.8M, -8.9% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $730.3M, -0.3% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $676.8M, -3.3% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $681.1M, -1.4% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $632.1M, -7.1% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $681.2M, -6.7% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $610.8M, -9.8% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $638.5M, -6.3% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $649.7M, +2.8% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $667.5M, -2.0% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $585.4M, -4.2% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $651.6M, +2.1% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $653.0M, +0.5% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $693.2M, +3.9% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $592.1M, +1.1% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $651.0M, -0.1% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $656.4M, +0.5% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $43.2M, +10% on a year earlier; public on 12 Feb 2022
Quarter ended 31 Mar 2022: $28.9M, +48% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $14.3M, -39% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $24.1M, -31% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Mar 2023: $35.7M, +24% on a year earlier; public on 6 May 2023
Quarter ended 31 Mar 2024: $40.2M, +12% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $42.3M; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $40.2M; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $42.9M; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $34.4M, -14% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $45.7M, +8.1% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $31.7M, -21% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $45.8M, +6.7% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $30.0M, -13% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $32.0M, -30% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $31.2M, -1.6% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 473; public on 14 Feb 2022
31 Mar 2022 report: 474; public on 16 May 2022
30 Jun 2022 report: 464; public on 15 Aug 2022
30 Sep 2022 report: 446; public on 14 Nov 2022
31 Dec 2022 report: 432; public on 14 Feb 2023
31 Mar 2023 report: 468; public on 15 May 2023
30 Jun 2023 report: 428; public on 14 Aug 2023
30 Sep 2023 report: 431; public on 14 Nov 2023
31 Dec 2023 report: 451; public on 14 Feb 2024
31 Mar 2024 report: 446; public on 15 May 2024
30 Jun 2024 report: 411; public on 14 Aug 2024
30 Sep 2024 report: 406; public on 14 Nov 2024
31 Dec 2024 report: 435; public on 14 Feb 2025
31 Mar 2025 report: 406; public on 15 May 2025
30 Jun 2025 report: 363; public on 14 Aug 2025
30 Sep 2025 report: 372; public on 14 Nov 2025
31 Dec 2025 report: 378; public on 17 Feb 2026
31 Mar 2026 report: 385; public on 15 May 2026
30 Jun 2026 report: 391; public on 14 Aug 2026
30 Sep 2026 report: 413; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $80K published
Quarter from 1 Apr 2022: $80K published
Quarter from 1 Jul 2022: $80K published
Quarter from 1 Oct 2022: $80K published
Quarter from 1 Jan 2023: $80K published
Quarter from 1 Apr 2023: $80K published
Quarter from 1 Jul 2023: $80K published
Quarter from 1 Oct 2023: $80K published
Quarter from 1 Jan 2024: $80K published
Quarter from 1 Apr 2024: $80K published
Quarter from 1 Jul 2024: $80K published
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $80K published
Quarter from 1 Jul 2025: $80K published
Quarter from 1 Oct 2025: $80K published
Quarter from 1 Jan 2026: $80K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $100K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $1.2M (12 Nov 2026), 4.4× its normal reading; higher than 91% of its own history.
  • Short interest spike: had 1.5M shares sold short in the 29 May 2026 report, 1.2× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $1.4M in the last 12 months (the 12 months before: -$955K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 34 published in the last 12 months, -11% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 85 insider trades

Last 90 days: 3 sales, $1.2M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Courtney C EnloeEVP, General Counsel & SecSell902$386.17$348KForm 4
12 Nov 2026Jonathan P. DiVincenzoPresident & COOSell919$390.47$359KForm 4
12 Nov 2026James BarryEVP, President, LSGSell1,400$385.63$540KForm 4
13 May 2026Eva Anette EngelhardtEVP, President, CDGSell550$246.54$136KForm 4
10 Nov 2025James BarryEVP, President, LSGSell700$306.18$214KForm 4
18 Mar 2025Michael CrowleyEVP, GBL Commercial OperationsSellafter exercising options3,000$247.06$741KForm 4
10 Sep 2024Andrew J. LastEVP, Chief Operating OfficerSellafter exercising options3,000$329.94$990KForm 4
4 Sep 2024James BarryEVP, President, LSGSellafter exercising options623$330.49$206KForm 4

413 institutions reported shares at the end of Q3 2026, 68% of the shares outstanding; 60 opened a position, 38 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
First Eagle Investment Management, LLC2.5M8.88%$927.5M-2.8M-53%
BlackRock, Inc.1.7M6.29%$657.3M+41K+2.4%
Dimensional Fund Advisors LP886K3.20%$334.6M-59K-6.2%
Vanguard Capital Management LLC827K2.99%$312.4M+2300%
Vanguard Portfolio Management LLC812K2.93%$306.5M-4,634-0.6%
Ariel Investments, LLC789K2.85%$298.1M-27K-3.4%
Capital Research Global Investors596K2.15%$225.2M+153K+34%
State Street Corp575K2.08%$217.3M+3,447+0.6%
Earnest Partners LLC568K2.05%$214.5M-13K-2.2%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC561K2.03%$211.7M+142K+34%

Institutions that added the most shares between Q2 2026 and Q3 2026.

InstitutionShares% of companyValueChange vs Q2 2026
Neuberger Berman Group LLC396K1.43%$149.6M+284K+254%
FMR LLC (Fidelity)220K0.80%$83.1M+216K51 times as many
Capital Research Global Investors596K2.15%$225.2M+153K+34%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC561K2.03%$211.7M+142K+34%
Wellington Management Group LLP192K0.70%$72.7M+132K+219%

Company events

All 34 company events

In 12 months: 1 director or officer change, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
4 Aug 2026Restructuring costs announced8-K
24 Apr 2026Director or officer changeSame filing: shareholder vote results8-K
28 Jul 2025Director or officer change8-K
13 Feb 2025Restructuring costs announced8-K
20 Aug 2024Director or officer change8-K
26 Apr 2024Director or officer changeSame filing: shareholder vote results8-K
10 Apr 2024Director or officer change8-K
20 Mar 2024Director or officer change8-K

Reported lobbying spend: $20K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
27 Jul 2026EndedForbes-Tatefor Bio-Rad LaboratoriesIssues related to advanced diagnostic testing and laboratory tools.; Issues related to biomedical research and development; Issues related to pathogen surveillance.Medicare/Medicaid, Health issues, DefenseFiling
23 May 2020NewForbes-Tatefor Bio-Rad LaboratoriesIssues related to biomedical innovation.Health issuesFiling

The 5 newest of 150 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 2 Sep 2026Lobbying record

    BIO-RAD LABORATORIES: lobbying engagement terminated (FORBES-TATE) (dated 27 Jul 2026)

  2. 4 Aug 2026Filings record

    Restructuring costs announced

  3. 10 Jun 2026Short interest and volume change

    had 1.5M shares sold short in the 29 May 2026 report, 1.2× the same report last year.

    Same report last year: 1.2M; its normal report is 949K.

    See the evidence
    This period
    1.5M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    949K
    Typical spread (median absolute deviation)
    70K
    How far from its usual level
    +5.4
    Same report last year
    1.2M
    History used
    3,073 days
    2025-05-30: 1.2M2025-06-13: 891K2025-06-30: 895K2025-07-15: 894K2025-07-31: 917K2025-08-15: 1.0M2025-08-29: 1.0M2025-09-15: 1.1M2025-09-30: 834K2025-10-15: 1.1M2025-10-31: 931K2025-11-14: 868K2025-11-28: 988K2025-12-15: 899K2025-12-31: 864K2026-01-15: 792K2026-01-30: 819K2026-02-13: 951K2026-02-27: 947K2026-03-13: 1.0M2026-03-31: 1.2M2026-04-15: 1.1M2026-04-30: 1.1M2026-05-15: 1.3M2026-05-29: 1.5M
    the 29 May 2026 report24 earlier reportsnormal: 949K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 28 May 2026Short interest and volume change

    had 1.3M shares sold short in the 15 May 2026 report, 1.0× the same report last year.

    Same report last year: 1.3M; its normal report is 949K.

    See the evidence
    This period
    1.3M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    949K
    Typical spread (median absolute deviation)
    70K
    How far from its usual level
    +3.8
    Same report last year
    1.3M
    History used
    3,059 days
    2025-05-15: 1.3M2025-05-30: 1.2M2025-06-13: 891K2025-06-30: 895K2025-07-15: 894K2025-07-31: 917K2025-08-15: 1.0M2025-08-29: 1.0M2025-09-15: 1.1M2025-09-30: 834K2025-10-15: 1.1M2025-10-31: 931K2025-11-14: 868K2025-11-28: 988K2025-12-15: 899K2025-12-31: 864K2026-01-15: 792K2026-01-30: 819K2026-02-13: 951K2026-02-27: 947K2026-03-13: 1.0M2026-03-31: 1.2M2026-04-15: 1.1M2026-04-30: 1.1M2026-05-15: 1.3M
    the 15 May 2026 report24 earlier reportsnormal: 949K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 24 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 24 Apr 2026Filings record

    Director or officer change

  7. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    11558428
  8. 28 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 28 Jul 2025Filings record

    Director or officer change

  10. 13 Feb 2025Filings record

    Restructuring costs announced

  11. 25 Sep 2024Short interest and volume change

    had 1.3M shares sold short in the 13 Sep 2024 report, 3.5× the same report last year.

    Same report last year: 388K; its normal report is 583K.

    See the evidence
    This period
    1.3M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    583K
    Typical spread (median absolute deviation)
    140K
    How far from its usual level
    +3.7
    Same report last year
    388K
    History used
    2,450 days
    2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K2023-11-30: 649K2023-12-15: 503K2023-12-29: 453K2024-01-12: 521K2024-01-31: 527K2024-02-15: 587K2024-02-29: 503K2024-03-15: 579K2024-03-28: 565K2024-04-15: 688K2024-04-30: 733K2024-05-15: 653K2024-05-31: 752K2024-06-14: 868K2024-06-28: 1.3M2024-07-15: 1.4M2024-07-31: 1.3M2024-08-15: 940K2024-08-30: 1.0M2024-09-13: 1.3M
    the 13 Sep 2024 report24 earlier reportsnormal: 583K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 20 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 20 Aug 2024Filings record

    Director or officer change

  14. 10 Aug 2024Short interest and volume change

    had 1.3M shares sold short in the 31 Jul 2024 report, 3.8× the same report last year.

    Same report last year: 336K; its normal report is 546K.

    See the evidence
    This period
    1.3M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    546K
    Typical spread (median absolute deviation)
    119K
    How far from its usual level
    +4.1
    Same report last year
    336K
    History used
    2,406 days
    2023-07-31: 336K2023-08-15: 409K2023-08-31: 435K2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K2023-11-30: 649K2023-12-15: 503K2023-12-29: 453K2024-01-12: 521K2024-01-31: 527K2024-02-15: 587K2024-02-29: 503K2024-03-15: 579K2024-03-28: 565K2024-04-15: 688K2024-04-30: 733K2024-05-15: 653K2024-05-31: 752K2024-06-14: 868K2024-06-28: 1.3M2024-07-15: 1.4M2024-07-31: 1.3M
    the 31 Jul 2024 report24 earlier reportsnormal: 546K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 25 Jul 2024Short interest and volume change

    had 1.4M shares sold short in the 15 Jul 2024 report, 4.3× the same report last year.

    Same report last year: 333K; its normal report is 524K.

    See the evidence
    This period
    1.4M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    524K
    Typical spread (median absolute deviation)
    120K
    How far from its usual level
    +5.0
    Same report last year
    333K
    History used
    2,390 days
    2023-07-14: 333K2023-07-31: 336K2023-08-15: 409K2023-08-31: 435K2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K2023-11-30: 649K2023-12-15: 503K2023-12-29: 453K2024-01-12: 521K2024-01-31: 527K2024-02-15: 587K2024-02-29: 503K2024-03-15: 579K2024-03-28: 565K2024-04-15: 688K2024-04-30: 733K2024-05-15: 653K2024-05-31: 752K2024-06-14: 868K2024-06-28: 1.3M2024-07-15: 1.4M
    the 15 Jul 2024 report24 earlier reportsnormal: 524K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 11 Jul 2024Short interest and volume change

    had 1.3M shares sold short in the 28 Jun 2024 report, 4.5× the same report last year.

    Same report last year: 283K; its normal report is 512K.

    See the evidence
    This period
    1.3M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    512K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +4.6
    Same report last year
    283K
    History used
    2,373 days
    2023-06-30: 283K2023-07-14: 333K2023-07-31: 336K2023-08-15: 409K2023-08-31: 435K2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K2023-11-30: 649K2023-12-15: 503K2023-12-29: 453K2024-01-12: 521K2024-01-31: 527K2024-02-15: 587K2024-02-29: 503K2024-03-15: 579K2024-03-28: 565K2024-04-15: 688K2024-04-30: 733K2024-05-15: 653K2024-05-31: 752K2024-06-14: 868K2024-06-28: 1.3M
    the 28 Jun 2024 report24 earlier reportsnormal: 512K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 26 Apr 2024Filings record

    Director or officer change

  18. 10 Apr 2024Filings record

    Director or officer change

  19. 20 Mar 2024Filings record

    Director or officer change

  20. 14 Feb 2024Filings record

    Director or officer change

  21. 14 Feb 2024Filings record

    A major agreement ended

  22. 12 Dec 2023Short interest and volume change

    had 649K shares sold short in the 30 Nov 2023 report, 3.3× the same report last year.

    Same report last year: 198K; its normal report is 287K.

    See the evidence
    This period
    649K (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    287K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +5.2
    Same report last year
    198K
    History used
    2,162 days
    2022-11-30: 198K2022-12-15: 232K2022-12-30: 252K2023-01-13: 278K2023-01-31: 250K2023-02-15: 245K2023-02-28: 279K2023-03-15: 362K2023-03-31: 265K2023-04-14: 274K2023-04-28: 236K2023-05-15: 291K2023-05-31: 384K2023-06-15: 281K2023-06-30: 283K2023-07-14: 333K2023-07-31: 336K2023-08-15: 409K2023-08-31: 435K2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K2023-11-30: 649K
    the 30 Nov 2023 report24 earlier reportsnormal: 287K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 7 Dec 2023Filings record

    Director or officer change

  24. 28 Nov 2023Short interest and volume change

    had 572K shares sold short in the 15 Nov 2023 report, 2.0× the same report last year.

    Same report last year: 284K; its normal report is 284K.

    See the evidence
    This period
    572K (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    284K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +4.1
    Same report last year
    284K
    History used
    2,147 days
    2022-11-15: 284K2022-11-30: 198K2022-12-15: 232K2022-12-30: 252K2023-01-13: 278K2023-01-31: 250K2023-02-15: 245K2023-02-28: 279K2023-03-15: 362K2023-03-31: 265K2023-04-14: 274K2023-04-28: 236K2023-05-15: 291K2023-05-31: 384K2023-06-15: 281K2023-06-30: 283K2023-07-14: 333K2023-07-31: 336K2023-08-15: 409K2023-08-31: 435K2023-09-15: 388K2023-09-29: 331K2023-10-13: 337K2023-10-31: 418K2023-11-15: 572K
    the 15 Nov 2023 report24 earlier reportsnormal: 284K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 18 Oct 2023Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DEF']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12618104
  26. 17 Oct 2023Filings record

    Director or officer change

  27. 25 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 25 Aug 2023Filings record

    Director or officer change

  29. 3 Aug 2022Institutional holdings record

    Veritas Asset Management LLP opened a $380.0M position (2022Q2 13F)

  30. 28 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 28 Mar 2022Filings record

    Director or officer change

  32. 2 Nov 2021Financials change

    spent $34.6M on capital projects in the quarter ended 30 Sep 2021, 1.7× the same quarter last year.

    Same quarter last year: $20.0M; its normal quarter is $21.6M.

    See the evidence
    This period
    $34.6M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $21.6M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +4.6
    Same quarter last year
    $20.0M
    History used
    3,745 days
    2019-09-30: $31.1M2019-12-31: $21.6M2020-03-31: $21.6M2020-06-30: $18.1M2020-09-30: $20.0M2020-12-31: $39.2M2021-03-31: $19.5M2021-06-30: $23.4M2021-09-30: $34.6M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $21.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 4 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 4 Oct 2021Filings record

    Director or officer change

  35. 23 Feb 2021Financials change

    reported revenue of $789.8M for the quarter ended 31 Dec 2020, 1.3× the same quarter last year.

    Same quarter last year: $624.5M; its normal quarter is $572.1M.

    See the evidence
    This period
    $789.8M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $572.1M
    Typical spread (median absolute deviation)
    $26.7M
    How far from its usual level
    +3.8
    Same quarter last year
    $624.5M
    History used
    4,202 days
    2018-12-31: $616.9M2019-03-31: $554.0M2019-06-30: $572.6M2019-09-30: $560.6M2019-12-31: $624.5M2020-03-31: $571.6M2020-06-30: $536.9M2020-09-30: $647.3M2020-12-31: $789.8M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $572.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  36. 23 Feb 2021Financials change

    spent $39.2M on capital projects in the quarter ended 31 Dec 2020, 1.8× the same quarter last year.

    Same quarter last year: $21.6M; its normal quarter is $21.9M.

    See the evidence
    This period
    $39.2M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $21.9M
    Typical spread (median absolute deviation)
    $1.8M
    How far from its usual level
    +6.4
    Same quarter last year
    $21.6M
    History used
    3,472 days
    2018-12-31: $53.9M2019-03-31: $23.6M2019-06-30: $22.2M2019-09-30: $31.1M2019-12-31: $21.6M2020-03-31: $21.6M2020-06-30: $18.1M2020-09-30: $20.0M2020-12-31: $39.2M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $21.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  37. 4 Feb 2021Filings record

    Restructuring costs announced

  38. 2 Jul 2020Lobbying change

    registered for federal lobbying for the first time in our data (Forbes-Tate).

    See the evidence (1 source record)
    Source coverage starts
    5 Oct 2010
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  39. 2 Jul 2020Lobbying record

    BIO-RAD LABORATORIES: new lobbying registration (FORBES-TATE) (dated 23 May 2020)

  40. 6 Apr 2020Filings record

    Director or officer change

Showing the newest 40 of 59 entries; narrow the window or the kind of data to see older ones.

Not listed: 191 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000012208
Ticker
BIO
Domain
bio-rad.com
Employer name
Bio-Rad Laboratories, Inc. (1 unverified)
Hq location
CA|HERCULES|94547 (1 unverified)
Lobbying client
bio rad laboratories
Name
Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad 1, Bio-Rad AbD Serotec GmbH and 47 more
Wikidata
Q2904022
Wikipedia
Bio-Rad Laboratories
  • DOL H-1B labor condition applications and PERM certifications928 data points14 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)2 records, 78 data points23 May 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)137 records25 Feb 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1217 data points31 Dec 2007 to 30 Sep 2026
  • SEC Form 4 insider transactions85 records, 268 data points14 Mar 2016 to 12 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026